Management of thrombotic diseases.
D000925:Anticoagulants / Q000494:pharmacology; D001241:Aspirin / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D003327:Coronary Disease / Q000188:drug therapy; D003374:Coumarins / Q000627:therapeutic use; D003911:Dextrans / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D004336:Drug Antagonism; D004342:Drug Hypersensitivity; D005340:Fibrinogen; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006350:Heart Valve Prosthesis; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D007192:Indenes / Q000009:adverse effects; D002542:Intracranial Embolism and Thrombosis / Q000517:prevention & control; D007456:Iodine Isotopes; D010973:Platelet Adhesiveness / Q000187:drug effects; D011453:Prostaglandins / Q000627:therapeutic use; D012110:Reserpine / Q000627:therapeutic use; D012214:Rheumatic Heart Disease / Q000097:blood; D013300:Streptokinase / Q000009:adverse effects; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy* / Q000517:prevention & control
D000925:Anticoagulants; D003374:Coumarins; D003911:Dextrans; D005343:Fibrinolytic Agents; D006634:Histamine H1 Antagonists; D007192:Indenes; D007456:Iodine Isotopes; D011453:Prostaglandins; D004176:Dipyridamole; D012110:Reserpine; D005340:Fibrinogen; D006493:Heparin; D013300:Streptokinase; D001241:Aspirin; D013442:Sulfinpyrazone; D006854:Hydrocortisone